HUTCHMED (China) Limited (H7T1) - Net Assets

Latest as of June 2025: €1.24 Billion EUR ≈ $1.45 Billion USD

Based on the latest financial reports, HUTCHMED (China) Limited (H7T1) has net assets worth €1.24 Billion EUR (≈ $1.45 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.78 Billion ≈ $2.08 Billion USD) and total liabilities (€534.02 Million ≈ $624.32 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check H7T1 asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets €1.24 Billion
% of Total Assets 69.93%
Annual Growth Rate 18.09%
5-Year Change 48.73%
10-Year Change N/A
Growth Volatility 59.53

HUTCHMED (China) Limited - Net Assets Trend (2016–2024)

This chart illustrates how HUTCHMED (China) Limited's net assets have evolved over time, based on quarterly financial data. Also explore H7T1 asset base for the complete picture of this company's asset base.

Annual Net Assets for HUTCHMED (China) Limited (2016–2024)

The table below shows the annual net assets of HUTCHMED (China) Limited from 2016 to 2024. For live valuation and market cap data, see HUTCHMED (China) Limited stock valuation.

Year Net Assets Change
2024-12-31 €771.85 Million
≈ $902.38 Million		 +3.83%
2023-12-31 €743.39 Million
≈ $869.10 Million		 +16.73%
2022-12-31 €636.87 Million
≈ $744.57 Million		 -38.73%
2021-12-31 €1.04 Billion
≈ $1.22 Billion		 +100.31%
2020-12-31 €518.95 Million
≈ $606.71 Million		 +65.85%
2019-12-31 €312.90 Million
≈ $365.82 Million		 -24.10%
2018-12-31 €412.25 Million
≈ $481.97 Million		 -14.99%
2017-12-31 €484.97 Million
≈ $566.98 Million		 +137.66%
2016-12-31 €204.06 Million
≈ $238.57 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to HUTCHMED (China) Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 75281500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Other Components €1.59 Billion 209.64%
Total Equity €759.93 Million 100.00%

HUTCHMED (China) Limited Competitors by Market Cap

The table below lists competitors of HUTCHMED (China) Limited ranked by their market capitalization.

Company Market Cap
Beijing Zhong Ke San Huan High-Tech Co Ltd
SHE:000970
 $2.15 Billion
Ströer SE & Co. KGaA
F:SAX
 $2.15 Billion
Longshine Technology Co Ltd
SHE:300682
 $2.15 Billion
Huada Automotive Tech Corp Ltd
SHG:603358
 $2.15 Billion
Sichuan Anning Iron and Titanium Co
SHE:002978
 $2.15 Billion
Roshow Technology Co Ltd
SHE:002617
 $2.15 Billion
Triumph Science & Technology Co Ltd
SHG:600552
 $2.15 Billion
Mtar Technologies Limited
NSE:MTARTECH
 $2.15 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in HUTCHMED (China) Limited's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 730,541,000 to 759,929,000, a change of 29,388,000 (4.0%).
  • Net income of 37,729,000 contributed positively to equity growth.
  • Share repurchases of 36,064,000 reduced equity.
  • New share issuances of 790,000 increased equity.
  • Other factors increased equity by 26,933,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income €37.73 Million +4.96%
Share Repurchases €36.06 Million -4.75%
Share Issuances €790.00K +0.1%
Other Changes €26.93 Million +3.54%
Total Change €- 4.02%

Book Value vs Market Value Analysis

This analysis compares HUTCHMED (China) Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 12.60x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 16.12x to 12.60x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-12-31 €0.69 €11.20 x
2018-12-31 €0.58 €11.20 x
2019-12-31 €0.43 €11.20 x
2020-12-31 €0.67 €11.20 x
2021-12-31 €1.14 €11.20 x
2022-12-31 €0.71 €11.20 x
2023-12-31 €0.86 €11.20 x
2024-12-31 €0.89 €11.20 x

Capital Efficiency Dashboard

This dashboard shows how efficiently HUTCHMED (China) Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 4.96%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 5.99%
  • • Asset Turnover: 0.49x
  • • Equity Multiplier: 1.68x
  • Recent ROE (4.96%) is above the historical average (-15.73%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2016 6.35% 5.41% 0.63x 1.86x €-6.73 Million
2017 -5.79% -11.08% 0.40x 1.29x €-72.91 Million
2018 -19.23% -34.94% 0.40x 1.37x €-113.70 Million
2019 -36.81% -51.75% 0.44x 1.61x €-134.83 Million
2020 -25.97% -55.15% 0.31x 1.50x €-174.14 Million
2021 -19.72% -54.66% 0.26x 1.39x €-293.34 Million
2022 -59.12% -84.62% 0.41x 1.69x €-421.87 Million
2023 13.80% 12.03% 0.65x 1.75x €27.73 Million
2024 4.96% 5.99% 0.49x 1.68x €-38.26 Million

Industry Comparison

This section compares HUTCHMED (China) Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $676,868,481
  • Average return on equity (ROE) among peers: -100.00%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
HUTCHMED (China) Limited (H7T1) €1.24 Billion 6.35% 0.43x $2.15 Billion
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) $5.52 Billion 11.33% 0.42x $635.99 Million
AYURCANN HOLDINGS CORP. (3ZQ0) $534.88K -741.80% 26.77x $113.81K
LORDS CO. WORLDW. HOLD. (4XM) $-1.01 Million 0.00% 0.00x $134.78K
EQL PHARMA AB (7JK) $123.63 Million 25.52% 0.92x $148.83 Million
Alkermes plc (8AK) $1.11 Billion -4.33% 0.82x $5.00 Billion
OPTIMI HEALTH CORP. (8BN) $6.57 Million -56.49% 1.32x $17.99 Million
LABIANA HEALTH S.A.EO-10 (8RK) $2.57 Million 9.87% 19.25x $40.60 Million
CANNABIS POLAND AB ZY-10 (8TE) $321.96K -209.89% 1.07x $1.75 Million
Apontis Pharma AG (APPH) $3.46 Million -34.21% 7.59x $91.63 Million
CRAFTPORT CANNABIS CORP. (BBW0) $-3.18 Million 0.00% 0.00x $1.45 Million

About HUTCHMED (China) Limited

F:H7T1 Germany Drug Manufacturers - Specialty & Generic
Market Cap
$2.25 Billion
€1.93 Billion EUR
Market Cap Rank
#5995 Global
#904 in Germany
Share Price
€11.20
Change (1 day)
-0.88%
52-Week Range
€10.80 - €15.90
All Time High
€36.80
Categories
Companies in Germany Drug Manufacturers - Specialty & Generic
About

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), b… Read more